These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23899530)

  • 1. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
    Reni M; Cereda S; Milella M; Novarino A; Passardi A; Mambrini A; Di Lucca G; Aprile G; Belli C; Danova M; Bergamo F; Franceschi E; Fugazza C; Ceraulo D; Villa E
    Eur J Cancer; 2013 Nov; 49(17):3609-15. PubMed ID: 23899530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
    O'Reilly EM; Niedzwiecki D; Hall M; Hollis D; Bekaii-Saab T; Pluard T; Douglas K; Abou-Alfa GK; Kindler HL; Schilsky RL; Goldberg RM;
    Oncologist; 2010; 15(12):1310-9. PubMed ID: 21148613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
    Bergmann L; Maute L; Heil G; Rüssel J; Weidmann E; Köberle D; Fuxius S; Weigang-Köhler K; Aulitzky WE; Wörmann B; Hartung G; Moritz B; Edler L; Burkholder I; Scheulen ME; Richly H
    Eur J Cancer; 2015 Jan; 51(1):27-36. PubMed ID: 25459392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
    Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
    J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.
    Yi JH; Thongprasert S; Lee J; Doval DC; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Eur J Cancer; 2012 Jan; 48(2):196-201. PubMed ID: 22176869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
    J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
    Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
    Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
    Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
    Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
    J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
    Sonpavde G; Hutson TE; Berry WR; Boehm KA; Asmar L
    Clin Genitourin Cancer; 2008 Sep; 6(2):134-7. PubMed ID: 18824440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
    Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
    Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
    Gervais R; Hainsworth JD; Blais N; Besse B; Laskin J; Hamm JT; Lipton A; Albain KS; Masters GA; Natale RB; Selaru P; Kim ST; Chao RC; Page RD
    Lung Cancer; 2011 Dec; 74(3):474-80. PubMed ID: 21680048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib and pancreatic neuroendocrine tumours. More assessment needed.
    Prescrire Int; 2012 May; 21(127):123-5. PubMed ID: 22827001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
    Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
    BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.